Arris Issued First Two Patents.SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BUSINESS WIRE)--July 1, 1996-- Arris ar·ris n. pl. arris or ar·ris·es The sharp edge or ridge formed by two surfaces meeting at an angle, as in a molding. [Alteration of Old French areste, fishbone, spine Pharmaceutical Corporation (Nasdaq: ARRS ARRS American Roentgen Ray Society. ) announced today that on June 11, 1996 the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property issued two patents to the Company. The first, U.S. Patent No. 5,525,623 entitled "Compositions and Methods for the Treatment of Immunomediated Inflammatory Disorders," relates to the Company's tryptase inhibitor APC-366 and structural analogs thereof and the pharmaceutical compositions containing them and their uses as therapeutic agents. The second patent, No. 5,526,281 entitled "Machine-Learning Approach to Modeling Biological Activity for Molecular Design and to Modeling Other Characteristics," relates to the underlying mathematical foundation for the Company's proprietary computational approach to drug design. According to president and chief executive officer John P. Walker, "The two patents which relate to our lead compound and our computational tools are important because they recognize the strength of the integrated technologies which underlie our discovery platform as well as their productivity in the discovery of novel chemical entities. In addition, the first patent underscores the strength of our protease-based technology and equally as important, establishes the proprietary position of our clinical program." The company also noted that the computational approach to drug design that is the subject of the newly issued patent is unique to Arris, and that the company is continuing to develop new tools based on its foundation. The tools allow for sophisticated treatment of molecules, greatly reducing guesswork about the types of molecular structures that might bind to or "dock" with a target. Arris said that the structures of many thousands of organic molecules may be manipulated and assessed with these tools in a much shorter period of time and more accurately than commercially available systems may allow. Arris Pharmaceutical uses an integrated drug discovery approach combining structure-based drug design, combinatorial chemistry and its proprietary Delta technology to discover and develop small molecule therapeutics for existing markets where available therapies have significant limitations. Arris' product development programs include: protease-based discovery programs targeting the inhibition of enzymes implicated im·pli·cate tr.v. im·pli·cat·ed, im·pli·cat·ing, im·pli·cates 1. To involve or connect intimately or incriminatingly: evidence that implicates others in the plot. 2. in inflammatory and certain other diseases such as asthma, blood clotting disorders, arthritis, osteoporosis, cancer and various infectious disease; and receptor-based discovery programs, including those designed to discover small molecule drugs that mimic therapeutically important proteins, such as EPO EPO see erythropoietin. EPO Erythropoietin, see there , hGH, G-CSF G-CSF granulocyte colony-stimulating factor. G-CSF granulocyte-colony stimulating factor. G-CSF Granulocyte colony-stimulating factor Molecular therapeutics A biological response modifier, the recombinant DNA form of and TPO (Twisted Pair Only) Refers to the use of twisted pair wire when other options are available. For example, a TPO suffix at the end of 3com Ethernet adapter model numbers indicates the card has only an RJ45 connector. , and research programs to develop drugs that modulate the activity of receptors involved in diseases such as cancer and diabetes. CONTACT: Arris Pharmaceutical Corporation, South San Francisco John Walker/Shari Annes, 415/829-1000 http://www.arris.com |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion